GlaxoSmithKline, AstraZeneca butt heads over licensing rights to key PARP inhibitor — report
Ahead of GlaxoSmithKline’s planned split into two companies and spin-off of its consumer divisions, the pharma’s major British rival is reportedly suing over a drug that could prove pivotal to CEO Emma Walmsley’s plans.
AstraZeneca has filed a court claim in the UK arguing for a larger share of sales from the GSK cancer drug Zejula, the Times of London reported Sunday. Zejula, the centerpiece of GSK’s $5 billion acquisition of Tesaro from late 2018, was developed in part by technology owned by AstraZeneca and is licensed to GSK.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 109,500+ biopharma pros reading Endpoints daily — and it's free.